Pluristem Therapeutics Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pluristem Therapeutics Inc. on July 7, 2017. The company, incorporated in Nevada with principal offices in Haifa, Israel, is reporting the entry into a material definitive agreement regarding the potential sale of its common stock.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial metric disclosed is the authorization to raise up to $80 million in aggregate offering price through an At Market Issuance Sales Agreement.
Material Changes and Agreements
- At Market Issuance Sales Agreement: On July 7, 2017, Pluristem entered into an agreement with Oppenheimer & Co. Inc., FBR Capital Markets & Co., and MLV & Co. LLC (collectively, the Agents).
- Offering Structure: The company may issue and sell shares of common stock having an aggregate offering price of up to $80 million from time to time.
- Sales Method: Sales will be conducted as "at the market offerings" under Rule 415 of the Securities Act of 1933, utilizing a currently effective shelf registration statement on Form S-3.
- Compensation: Pluristem will pay the Agents a commission of up to 3.0% of the gross proceeds from any shares sold.
- Termination: The agreement may be terminated by either party upon 2 days' notice or automatically upon the sale of all subject common stock.
Guidance, Outlook, and Risks
Management commentary indicates that Pluristem is not obligated to make any sales under the agreement. The filing explicitly states that no assurance can be given that the company will sell any shares, nor can the price, amount, or timing of any potential sales be determined. The agreement is subject to customary indemnification rights and the terms of the Sales Agreement filed as Exhibit 10.1.
Investor Verification Checklist
- Verify the full text of the At Market Issuance Sales Agreement (Exhibit 10.1) for specific conditions and limitations.
- Review the company's current effective shelf registration statement on Form S-3 (File No. 333-218916).
- Monitor future filings for actual sales activity, as the agreement does not guarantee any stock issuance.
- Confirm the affiliation status of FBR Capital Markets & Co. and MLV & Co. LLC as disclosed in the filing.